Featured News See All November 18, 2024 REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA November 14, 2024 REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 November 6, 2024 REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates Year All202420232022202120202019201820172016201520142013201220112009 May 08, 2024 REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights May 01, 2024 REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights Apr 24, 2024 REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Mar 28, 2024 REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD Mar 27, 2024 REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days Mar 11, 2024 REGENXBIO to Participate in Upcoming Investor Conferences Mar 06, 2024 REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
May 08, 2024 REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
May 01, 2024 REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
Apr 24, 2024 REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Mar 28, 2024 REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
Mar 06, 2024 REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
